InSilico Medicine Cayman TopCo (INSILICO, HKEX: 03696) has updated its share capital movements in a Next Day Disclosure Return dated 17 November 2026, detailing simultaneous share issuance under employee options and an on-market repurchase.
• Capital changes – Opening balance on 16 November 2026: 586.89 million issued shares (excluding treasury). – New shares issued: 44,433 ordinary shares were allotted on 17 November upon exercise of options granted under the company’s Pre-IPO Equity Incentive Plans, equivalent to 0.0076 % of the pre-event share base. The volume-weighted issue price was HKD 3.2463 per share. – Share buyback: On the same day, INSILICO repurchased 369,000 shares on the Exchange at prices ranging between HKD 34.06 and HKD 34.26, for a total consideration of HKD 12.61 million. These shares are being held as treasury stock. – Net effect: Issued shares outstanding (excluding treasury) decreased by 324,567 to 586.56 million, a 0.06 % reduction. Treasury shares rose from 1.16 million to 1.53 million. Total issued shares (including treasury) stood at 588.09 million after the transactions.
• Repurchase mandate utilisation – The board’s repurchase mandate approved on 2 June 2026 allows for the buyback of up to 57.24 million shares. – Cumulative repurchases under this mandate now total 1.53 million shares, representing 0.27 % of the company’s issued share capital at the mandate date. – A 30-day moratorium on new share issuance or treasury share sales is in effect until 17 December 2026, in line with Hong Kong listing rules.
• Compliance statement The company confirmed that all share issues and repurchases were duly authorised by the board and executed in accordance with the Hong Kong Stock Exchange listing rules and relevant regulations.
Comments